文献速递乳腺癌

Ki67增殖指数作为乳腺癌新辅助芳香化酶抑制剂治疗期间及之后化疗决策工具:美国外科医师学会肿瘤学组Z1031试验(Alliance)结果

Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
PubMed 文献 · J Clin Oncol · 2017-01-03

ACOSOG Z1031B研究纳入绝经后II-III期ER阳性乳腺癌患者,新辅助芳香化酶抑制剂(AI)治疗2-4周后Ki67>10%者转为新辅助化疗,pCR率仅5.7%(95%CI 0.7%-19.1%),低于预设20%阈值。完成新辅助AI者中,PEPI=0组5年复发风险3.7%,显著低于PEPI>0组的14.4%(HR 0.27,P=0.014)。

要点

  • AI治疗2-4周后Ki67>10%的ER阳性乳腺癌,新辅助化疗pCR率仅5.7%,低于20%预设阈值。
  • PEPI=0组5年复发率3.7%,PEPI>0组14.4%,HR 0.27(95%CI 0.092-0.764,P=0.014)。
  • PEPI=0患者5年无化疗复发风险仅3.6%,支持辅助内分泌单药治疗研究。

核心结论

  • ER阳性且对AI增殖抵抗的肿瘤化疗疗效低于预期,这些患者的最佳治疗需进一步研究。
  • PEPI=0患者5年无化疗复发风险仅3.6%,支持在该组研究辅助内分泌单药治疗。
  • Ki67和PEPI分诊方法正在ALTERNATE试验(NCT01953588)中确证性研究。

研究设计与样本

  • ACOSOG Z1031A试验入组绝经后II或III期ER阳性(Allred评分6-8)乳腺癌患者,随机接受阿那曲唑、依西美坦或来曲唑新辅助AI治疗。
  • ACOSOG Z1031B方案修订为AI治疗2-4周后检测肿瘤Ki67,Ki67>10%者转为新辅助化疗。
  • 预设pCR疗效阈值为>20%。
  • 完成新辅助AI者采用分层Cox模型评估PEPI=0(T1或T2、N0、Ki67<2.7%、ER Allred>2)与PEPI>0的复发时间差异。

主要发现

  • ACOSOG Z1031B中35例转为新辅助化疗者仅2例达pCR(5.7%;95%CI 0.7%-19.1%)。
  • 中位随访5.5年,PEPI=0组109例中4例(3.7%)复发,PEPI>0组341例中49例(14.4%)复发。
  • PEPI=0 vs PEPI>0的复发风险HR 0.27(95%CI 0.092-0.764;P=0.014)。

关键数值与推荐

  • Ki67>10%(AI治疗2-4周后)为转为新辅助化疗的阈值。
  • PEPI=0定义:T1或T2、N0、Ki67<2.7%、ER Allred>2。
  • 预设pCR疗效阈值为>20%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose To determine the pathologic complete response (pCR) rate in estrogen receptor (ER) -positive primary breast cancer triaged to chemotherapy when the protein encoded by the MKI67 gene (Ki67) level was > 10% after 2 to 4 weeks of neoadjuvant aromatase inhibitor (AI) therapy. A second objective was to examine risk of relapse using the Ki67-based Preoperative Endocrine Prognostic Index (PEPI). Methods The American College of Surgeons Oncology Group (ACOSOG) Z1031A trial enrolled postmenopausal women with stage II or III ER-positive (Allred score, 6 to 8) breast cancer whose treatment was randomly assigned to neoadjuvant AI therapy with anastrozole, exemestane, or letrozole. For the trial ACOSOG Z1031B, the protocol was amended to include a tumor Ki67 determination after 2 to 4 weeks of AI. If the Ki67 was > 10%, patients were switched to neoadjuvant chemotherapy. A pCR rate of > 20% was the predefined efficacy threshold. In patients who completed neoadjuvant AI, stratified Cox modeling was used to assess whether time to recurrence differed by PEPI = 0 score (T1 or T2, N0, Ki67 < 2.7%, ER Allred > 2) versus PEPI > 0 disease. Results Only two of the 35 patients in ACOSOG Z1031B who were switched to neoadjuvant chemotherapy experienced a pCR (5.7%; 95% CI, 0.7% to 19.1%). After 5.5 years of median follow-up, four (3.7%) of the 109 patients with a PEPI = 0 score relapsed versus 49 (14.4%) of 341 of patients with PEPI > 0 (recurrence hazard ratio [PEPI = 0 v PEPI > 0], 0.27; P = .014; 95% CI, 0.092 to 0.764). Conclusion Chemotherapy efficacy was lower than expected in ER-positive tumors exhibiting AI-resistant proliferation. The optimal therapy for these patients should be further investigated. For patients with PEPI = 0 disease, the relapse risk over 5 years was only 3.6% without chemotherapy, supporting the study of adjuvant endocrine monotherapy in this group. These Ki67 and PEPI triage approaches are being definitively studied in the ALTERNATE trial (Alternate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuvant Treatment in Postmenopausal Women: A Phase III Study; clinical trial information: NCT01953588).

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Ellis MJ, Suman VJ, Hoog J, et al. Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance). J Clin Oncol. 2017. PMID: 28045625. doi:10.1200/JCO.2016.69.4406

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。